News & Events

News


Friday April 03, 2020

Neurocrine Biosciences Provides COVID-19 Business Update

SAN DIEGO , April 3, 2020 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update regarding the company's business operations during the COVID-19 pandemic as part of its commitment to prioritize the safety, health and well-being of patients, their caregivers,


Thursday March 19, 2020

Neurocrine Biosciences Statement in Response to COVID-19

As we continue to monitor COVID-19 developments, at Neurocrine Biosciences we are committed to the safety, health and well-being of our patients, customers and employees. To healthcare providers and their patients with tardive dyskinesia, we do not anticipate any disruption in our ability to supply


Tuesday February 25, 2020

Neurocrine Biosciences to Present at Cowen 40th Annual Health Care Conference

Live Audio Webcast will be on March 3, 2020 SAN DIEGO , Feb. 25, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 40 th Annual Health Care Conference at 12:00 p.m. Eastern Time on Tuesday, Mar. 3, 2020 , in Boston .


Tuesday February 04, 2020

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results

INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx INGREZZA® (valbenazine) Full-Year 2019 Net Product Sales of $753 Million with Approximately 132,700 TRx SAN DIEGO , Feb. 4, 2020 /PRNewswire/ --  Neurocrine Biosciences, Inc.


Monday February 03, 2020

Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors

SAN DIEGO , Feb. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Shalini Sharp to its Board of Directors. Ms. Sharp is the Chief Financial Officer and Executive Vice President of Ultragenyx, a clinical-stage biopharmaceutical company focused on

Events